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Abstract 
The healthcare costs in the United States are growing at an alarming rate. With 
the costs expected to more than double in the next decade, the issue of what do about it 
has become a highly politicized topic. With many different constituencies offering their 
own solutions, focus has shifted away from the overall problem of health care costs and 
settled on the specific topic of the price of prescription drugs. This paper examines the 
increase in prescription drug expenditures, inspects why drugs cost as much as they do, 
reviews the patent laws concerning prescription drugs, and explores possible solutions to 
the problems caused by the inflated costs. This paper is not meant to provide an absolute 
answer to the problem of rising pharmaceutical expenditures, but it does propose a series 
of possible solutions which address not only the high costs of prescription drugs but also 
the difficulty of ensuring the uniformity of price reductions and the financial 
compensation required for the innovation of new drugs without sacrificing the quality of 
care that patients receive. 
-Costs of Drug Development 
According to an article in Newsweek, drug expenditures in the United States have 
increased from $65 billion in 1995 to $125 billion in 1999, and the article estimates that 
prescription-drug spending will reach $243 billion by the year 2008. 1 In order to discuss 
the effects of patent law on the price of prescription drugs, one must first investigate the 
costs associated with the discovery, development, and marketing of new drugs. Because 
patents do expire allowing generic drug competition and a consequential decrease in 
profits, phamlaceutical companies must compete by means of innovation. However, a 
company must first discover a new drug before it can introduce it to market. 
Seeing drug discovery as a way to broaden markets, increase profits, and increase 
the price of a company's stock, pharmaceutical companies in the United States have 
actively sought to increase the amount of money that they invest in discovery. The 
amount of money invested in research and development has risen from 11.9% of total 
sales or $1.5 billion in 1980 to 20.3% of sales or $22.5 billion in 2000.2 During this time 
period, companies have systematically accelerated the research process of discovering 
new drugs, and research teams used in the discovery process have changed. They have 
become larger and more academically diverse, allowing colleagues to put forth ideas 
from different academic disciplines to use and test numerous leads, and to systematically 
investigate numbers of related groups of compounds. 3 Another advantage to increasing 
the size of research groups is that it allows for further modification of compounds. In 
other words, different chemical groups can be added or deleted from compounds in order 
to increase solubility, to pass toxicology tests, or simply to discover more potent analogs. 
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Pfizer's Chairman and Chief Executive Officer William C. Steere, Jr. contributes 
Pfizer's industry-leading growth rate to its currently marketed human pharmaceutical 
products and its promising research pipeline. In an address to financial analysts on 
December 11,2000, he stated, "Pfizer's strong, sustained performance is driven by our 
strategic focus on innovative research and a diverse product line that addresses major 
unmet medical needs.',4 His statement was later echoed by President and Chief Operating 
Officer Henry A. McKinnell, Ph.D. Dr. McKinnell attributes Pfizer's continued growth 
to "a broad base of key products, a diverse new product pipeline, continuing profit 
margin expansion and investment for future growth." 4 Pfizer projects that the company 
will submit at least six new pharmaceutical candidates in the next two years for 
regulatory approval. These candidates include "innovative treatments for diabetes, 
neuropathic pain and epilepsy, and HIV/AIDS.,,4 In addition, the company also reports 
"significant progress in its research and development programs covering compounds for 
treating smoking cessation, cancer, depression and cardiovascular disease." 4 The Vice 
Chairman and President of Pfizer Global Research and Development, John F. Niblack, 
Ph.D., asserts that Pfizer is now the largest pharmaceutical research and development 
operation in the world. According to Dr. Niblack, Pfizer's research efforts include 
"approximately 12,000 employees, six discovery sites and an expected 2001 investment 
in total R&D of approximately $5 billion" that contain" 19 research areas, covering just 
about every major disease." 4 
In 1999, Eli Lilly and Company was one of the pharmaceutical industry leaders in 
the area of research and development investment with respect to total sales. According to 
an informational booklet distributed by Eli Lilly and Company in 2000, the emphasis on 
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research and development dates back to the company's founder, Colonel Eli Lilly, who 
was, himself, a pharmaceutical chemist. The booklet states that Colonel Lilly "vowed to 
develop products based on the best science of the day."s Under Colonel Lilly's 
leadership in the 1880's, "Lilly became one of the first companies to initiate a bona fide 
pharmaceutical research program." The company's emphasis on innovation did not stop 
there. Colonel Lilly's grandson, also named Eli, referred to research as "the heart ofthe 
business, the soul of the enterprise." S Today, the company continues to invest large 
amounts of capital to improve and expand the capabilities of their research and 
development division. The company has committed itself to hiring hundreds of new 
scientists "to strengthen and deepen [ their] expertise at all stages of research and 
development." S 
Investment in the research and discovery of new drugs is a vital component of the 
pharmaceutical industry. Pharmaceutical companies, like all other companies, exist to 
tum a profit. There are two ways of doing this. The first is simply to cut prices. After a 
drug has been discovered, it is covered under a patent granted by the government in order 
to allow a company to recoup the money invested in its discovery. However, the patent 
does expire. Following a patent expiration, other companies are allowed to make the 
product. After their product passes the stringent tests imposed by the Food and Drug 
Administration, it can be marketed. Multiple companies can essentially duplicate the 
compound and compete with the company that discovered the compound in the first 
place. When this happens, the companies compete for market shares. They compete 
through advertising campaigns and cutting prices. As long as the drugs are essentially 
the same, the only overriding factor is the cost. 
3 
While the price cutting strategy is simpler than discovering and developing new 
drugs, it is not a good way for a company to earn a profit. The lower the price is set, the 
lower a company's profits from the sale of the drug. In order to obtain large sales and to 
dominate a portion of the pharmaceutical market, a company must offer a unique drug. It 
must introduce either a drug that treats previously incurable diseases or it must offer 
some benefit over previous used drugs. For example, a benefit could be an extra strength 
drug, a more specialized drug, or one that has to be taken less frequently. This strategy 
for increasing profits is much riskier than the price cutting strategy because the firm must 
always make a large investment in research and development in order to discover and 
develop a new product which may win large sales but also runs a risk of failure. 6 This 
risk of failure drives up the already inflated costs of discovering new drugs. 
As mentioned earlier, companies have made concerted efforts to hire new 
scientists and expand the size of their research groups. While this is important, it is not 
all that can be: done to accelerate the research and development of new drugs. In order to 
accomplish this goal, companies must also invest in technology. They must buy new 
equipment, update older equipment, and utilize the latest technological discoveries. In 
addition, companies must also investigate biotechnology and other nontraditional fields 
in order to either discover new candidates or find quicker, more efficient ways to produce 
currently marketed pharmaceuticals. However, all these methods, combined with a 
lengthy approval process, and the previously mentioned failures of some compounds, 
have contributed to a dramatic increase in the cost of the research and development of 
new drugs. 
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The graph below shows the tremendous increase in the costs of the research and 
development per marketed drug. The costs have increased from $54 million in 1976,7 to 
$231 million in 1987,8 to $350 million in 1994,9 and to approximately $500 million in 
2000. 10 
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The dramatic increase in the costs of research and development has magnified the 
risks associated with the development of new pharmaceuticals. According to estimates, 
for every 5,000 substances examined, only one is likely to prove safe and effective. 11 In 
addition, once a drug is discovered, it takes an average of 12 years to bring it to market. 
When taking into consideration both the uncertainty of drug development as well as the 
time that it takes to bring a drug to market, it is easy to see why only 3 out of 10 Rx 
medicines recover that average cost. 11 
While the costs of discovering new compounds continue to increase, companies 
are becoming more dependent on their financially successful products in order to cover 
the costs of research and development of other compounds. For example, a 1992 survey 
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of major American pharmaceutical companies found that seven out often large 
pharmaceutical companies derive at least 50 percent of their sales from their three largest 
products. 12 It is important to realize that the financial benefits reaped by these 
companies for their top three products are not constant. After a patent expires for a 
particular compound, competition from generic drug makers begins, prices decrease, and 
the company that discovered the compound's market share decreases drastically. (The 
phenomenon of generic competition will be discussed in the next section of this paper.) 
Once a drug has been discovered, developed, and approved by government 
regulatory agencies, it is ready to be marketed. However, new drugs are not 
automatically prescribed by doctors and bought by patients. First companies must 
promote their products. In fact, drug companies have a higher ratio of promotion 
expenditures to sales in pharmaceuticals than in other industries. 13 In addition, doctors 
often complain about the excessive mailings that they receive as well as the personal 
visits from pharmaceutical salesmen. 
Despite the costs of these promotions, pharmaceutical companies continue to 
aggressively promote their products. They do this not to persuade doctors to over 
prescribe medications, but instead to educate doctors. By educating doctors, drug 
companies can inform them of new uses for drugs, newly found side effects, and new 
products that may be superior to products currently being used. Doctors do not prescribe 
new drugs immediately after they are introduced, partly out of caution but also out of 
ignorance. 14 Policies that are designed to limit the promotional expenses of drug 
companies run the risks of leaving doctors essentially unprepared to prescribe new 
medicines and to decrease the quality of therapy that they offer to their patients. 
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Research does not end just because a drug has been developed and brought to the 
market. Phannaceutical companies continue to research their products to search for new 
uses, different doses, ways to decrease the frequency that patients have to take pills, and 
continue to test their drugs' safety. Despite rigorous governmental testing, some drugs 
with potentially harmful side effects are marketed. The potential for harmful side effects 
leads to a pot(:ntial for lawsuits. Major pharmaceutical companies have always been 
concerned with these product liability lawsuits. However, they are more concerned with 
product liability concerns in the United States as opposed to cases in Canada and Europe. 
There are two reasons for this. The first is the evolution of strict liability lawsuits in the 
United States. These types of lawsuits allow for companies that produce products with 
manufacturing, design, or communications defects to be sued without the plaintiff 
establishing an injury or loss. Under these lawsuits, people can sue the companies for 
lack of infomtation and/or warning labels. 
Canadian and European courts have been less willing to hold manufacturers to the 
strict standards that the current United States legal system does. For example, market 
share liability, where a whole industry can be sued for lack of warning labels, is a unique 
characteristic of the American legal system. Additionally, United States courts have 
historically awarded much larger judgements than those of their foreign counterparts. 
One reason for this is that in the United States, litigants have the right to request jury 
trials in civil cases. Traditionally, juries are more willing than judges to favor plaintiffs 
at the expense of the deep pockets of a drug company. IS Judges in Canada and elsewhere 
are less likely to award large punitive and compensatory damages. In fact, damages that 
Canadian judges are able to award are often subject to statutory limits. 16 Additionally, 
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-Canadian litigants are limited in their rights of appeal. Legal costs are an expense for 
every pharmaceutical company. These costs are passed on to the consumers through 
increases in the price of the drugs. Legal costs are greater in the United States than in 
Canada or in the European Union. Therefore, the costs added to the price of drugs in the 
U.S. are greater, meaning that drugs are more expensive. 
8 
-US Patent Laws 
In order for phannaceutical companies to continue to invest in research and 
development, they must continue to see a return on their investments. In other words, the 
company must make a profit off of the drugs that they do manufacture. In order for a 
drug to become profitable, the price obtained from the sale of the drug must not only 
cover the costs of manufacturing, marketing, testing, and distributing the drug, but it also 
must be sufficient in reimbursing the company for the money that it invested in research 
and development. Like all businesses, a phannaceutical company shows a profit when its 
total income exceeds its total expenditures. When one considers that only one in 5,000 
substances that are examined is proven both safe and effective and only thirty percent of 
all prescription drugs recover the average costs of development, as discussed in the 
previous section, it becomes evident that not all drugs are profitable. Therefore, for a 
company to be profitable, it must return a higher than average profit on the thirty percent 
of the drugs that are able to recover the costs of development in order to offset the losses 
that the company incurs from the drugs that are not. 
In a free market system, however, it is next to impossible to recover these costs 
without governmental intervention. For in a free market society that is unimpeded by 
governmental intervention, it would be difficult to consistently return higher than average 
profits from the sale of anyone product. If a company was able to sell a product at an 
inflated price, then competing companies would enter the market and sell their own 
version of the product for a price lower than the initial company's price, and the initial 
company would essentially lose the money that it invested in the research and 
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-development of the product. Therefore, for pharmaceutical companies to become 
profitable, they must rely on governmental intervention to help them to recover the 
excessive costs associated with the research and development of their products. 
The means through which the United States government intervenes in the market 
is provided by Article 1 Section 8 of the Constitution. It states that "The Congress shall 
have the Power ... To promote the Progress of Science and useful Arts, by securing for 
limited Times to Authors and Inventors the exclusive Right to their respective Writings 
and Discoveries." 17 This article of the Constitution paved the way for the creation of the 
United States Patent and Trademark Office in 1802. 18 The patents that this office is 
authorized to grant prohibit others from making, using or selling the invention in the 
United States for a given period of time. 19 
Monopolies 
When a company first begins to market a new product, it is the sole supplier. 
Until competition is introduced into the market, the company can set the price as high as 
it likes. The consumer can either purchase the product from the supplier at the price set or 
not at all. This situation in which a single firm is the only supplier of a product or service 
for which buyers cannot easily find a substitute is known as a monopoly. 20 Monopolies 
of some form exist in every market and arise for a variety of reasons. The most common 
form of monopoly is when new products are introduced into markets. Initially, the 
company that first markets a new product is the beneficiary of a monopoly even if 
regulatory measures, such as patents and trademarks, are not available. The reason for 
this is that it takes time for competitors to produce and market competing products. Two 
other potential causes for monopolies deal with the market factors of supply and demand. 
10 
-A monopoly may exist because the market for the product is only big enough to support 
one supplier. In this case, the most efficient supplier that is able to produce the product at 
the lowest cost can essentially run the competing suppliers out of the market therefore 
establishing a monopoly for itself. Another way that a company can hold a monopoly is 
if it is able to control the entire supply of raw materials that are needed to produce a 
certain product. Without access to these raw materials, competing companies cannot 
produce their own versions of the product. 
In the pharmaceutical market, a monopoly is necessary to allow companies to 
recoup the money that they have invested in the research and development of their 
products. Patents and trademarks, granted by the government, create these monopolies 
for the companies. Some people argue that pharmaceutical patents are not necessary for 
two reasons. They argue that the lack of appropriate technology may prevent potential 
competitors from entering the market quickly.21 The assumption with this argument is 
that each drug is complex and that it is very difficult to acquire the technical knowledge 
that is required to produce it. The second argument is simply that pharmaceutical 
companies are innovative, and it does not take long for competition to arise, even if it is 
from a chemically different drug. In this instance, patent protection is essentially 
devalued by the prospect of another company being able to find a different way to treat a 
disease. 
The flaw in the first argument is that it is, in fact, rather easy for competitors to 
duplicate products. Companies are required to report a drug's chemical formula on its 
label. With the knowledge of the chemical formula, scientists at other companies can 
easily duplicate products. Due to the ease of replication, patents take on added 
11 
-importance for pharmaceutical companies. The flaw of the second argument lies both in 
the flaw of th{: first as well as in the degree of speculation that is assumed by the 
argument. While some drugs that are under patent protection do lose their share of the 
market to newer drugs, one cannot assume that just because a drug is successful that a 
competing drug will enter the market, let alone steal a large share of it. 
General Agreement on Tariffs and Trade 
On December 8, 1994, as a part of the General Agreement on Tariffs and Trade, 
the United States patent law was changed in order to make it similar to the ones used in 
other countries. Before this modification, the law had provided protection of new 
products for seventeen years from the date of issuance. 22 The General Agreement on 
Tariffs and Trade changed the law to provide patent protection for twenty years from the 
date of application. 23 Despite the appearance that the length of patent protection in the 
United States was extended through this law, some experts argue that this may not 
necessarily be the case. Lewis A. Engman, the president of the Generic Pharmaceutical 
Industry Association, stated, "The change in the law ultimately will benefit generic 
manufacturers by eliminating situations in which delays in granting of patents and 
multiple patents extend the term of effective protection." 24 His argument is that, in the 
past, pharmaceutical companies have received patent protection for periods of time 
longer than twenty years through delays in the issuance of patents. 
By definition, a patent gives the holder, or patentee, the right to exclude others 
from making, selling, or offering to sell the product or process claimed by the patentee 
for a specified period oftime.25 According to United States law, the specified period of 
time is twenty years. However, the effective or actual amount of time that the 
12 
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pharmaceutical company has to market a patented product may be considerably less. To 
obtain an estimate of the effective time that the company has to market the product under 
patent protection, one must first subtract the time that it takes for the patent office to 
approve the patent, since the law states that the twenty years begins with the date of 
application. An additional variable that must be taken into account is the amount of time 
that the FDA takes to approve the drug. While pharmaceutical companies typically apply 
for patents immediately after a compound has been synthesized and proven effective in 
animal tests, the company is not able to market the compound until after it has received 
approval from the FDA to do so. 
FDA Testing 
Befon: a drug can be tested on human subjects, a pharmaceutical company must 
first prove that is safe to test on people through preclinical laboratory and animal tests. 
Experts estimate that only five in 5000 pharmaceuticals that enter preclinical testing 
advance to human trials and of these five, only one will eventually be marketed as a new 
product. 26 Once substantial evidence has been gathered to prove that a drug is safe for 
human trials, a company can apply for permission to conduct these clinical trials through 
submitting an Investigational New Drug (IND) application. If the FDA does not 
comment adversely within thirty days of the application, then clinical testing may 
begin.27 
Clinical trials provide pharmaceutical companies with the opportunity to gather 
information concerning the safety, effectiveness, and dosage of a drug through testing it 
on human subjects. Clinical trials are typically divided into three phases. Phase I 
generally involves a relatively small number of healthy subjects. This phase can last 
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-several months and is used to determine any potential side effects of the drug. Assuming 
that everything goes well, the clinical trials are expanded from the twenty to one hundred 
patients tested in Phase I to several hundred patients in Phase II. As opposed to the 
healthy individuals used in Phase I, Phase II subjects actually have the condition the 
product is intended to treat. 28 Phase II studies are usual preformed through double-
blinded investigations, meaning that neither the patient nor the investigator knows 
whether the patient is receiving the drug or a placebo. These tests are conducted mainly 
to test the effe:ctiveness of the drug, but they are also used to determine the optimal 
dosage levels ofthe drug and to monitor any short-term side effects. Phase II clinical 
trials typically last from several months to two years. 
If a drug is permitted to move into Phase III clinical testing, it will be tested on a 
large number of subjects, often from several hundred to several thousand. These subjects 
are tested at different sites throughout the country and are involved in a second double-
blind study. The purpose of these tests is to determine the drug's effectiveness in 
comparison to certain controls, to determine the proper dosage of the drug, and to look 
for any potential long-term side effects. Phase III testing can last from one to four years. 
Once the clinical trials have concluded, the company can then submit a New Drug 
Application (NDA) to the FDA for review. Upon approval from the FDA, a company 
may begin marketing a new drug. Phase IV testing then begins. Phase IV testing 
involves surveys, samplings, and continued testing to investigate adverse reactions that 
people have to the drug. 
According to the United States Department of Health and Human Services, it 
takes an average of thirteen years eleven and a half months for a drug to go from the 
14 
initial synthesis, through the preclinical and clinical testing process and review by the 
FDA, to market. The pie graph below shows the average distribution of this time. 29 
New Drug Development Timeline 
NDA 
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(16.5 
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Clinical 
Testing 
(6 years) 
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Safety 
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(1 month) 
Preclinical 
Testing 
(6.5 years) 
Assuming that companies apply for patents near the start of clinical testing, the 
period of time that a drug is under patent, yet unmarketable, is on average approximately 
seven and a half years, leaving an average of only twelve and a half years for a company 
to market the drug while under patent protection. During these twelve and a half years, 
companies must price the drug high enough to recover the costs of its research and 
development, production, and marketing, while not pricing it too high and alienating the 
drug's market. As discussed earlier, a company must also work to cover the costs of 
other drugs that have not been able to recover the costs of their research and 
development. Any additional money that is made off of this drug is a profit for the 
company, which can choose to reinvest the money in further research. 
Patent Expiration 
Patent expiration occurs twenty years from the date of the initial application for a 
patent. After the patent has expired, the invention is public domain and can legally be 
reproduced and sold by anyone. 30 When a patent expires, the government created 
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monopoly that once existed is no more. Other companies begin to enter a drug's market 
almost immediately. And unlike the company that initially discovered the drug, 
subsequent companies' costs for research and development are incredibly low in 
comparison. For example, the entry barriers for duplicates, unlike new chemical entities 
are virtually nonexistent.3! The Waxman-Hatch Act of 1984 encourages the entry of 
generic pharmaceutical companies into the market by allowing use of the research 
undertaken on behalf of the pioneer product to gain generic approval. 32 In other words, 
the generic pharmaceutical company needs only to prove that their product contains the 
same active ingredient as the pioneering product. The company can rely upon the 
research of the pioneering company to provide information on the safety and efficacy of 
the drug. 
In addition to a real lack of entry barriers, a generic drug company does not rely 
on a large marketing campaign in order to steal a large share of the market. Instead, it 
appeals by offering the drug at a much lower price than the pioneering company. The 
company can do this because in comparison to the pioneering company, its overhead 
costs are virtually nonexistent. It does not pay for extensive research and development of 
new drugs, a large marketing campaign, or any other indirect costs like failed research 
projects searching for other potential drug candidates. In fact, because a generic 
pharmaceutical company has such low costs to produce a drug, it can sell it for a 
relatively small profit and therefore undercut the price of the product offered by the initial 
company. 
16 
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Cutting Costs 
During the 2000 presidential campaign, the Indianapolis Star reported after 
examining the prescription drug plans offered by the major party presidential candidates 
show that there is no miracle cure. 33 The article analyzed both the Bush and Gore plans 
for aiding senior citizens with the costs of prescription drugs. The two plans offered such 
initiatives as adding prescription drug benefits to Medicare, comprehensive Medicare 
reform, and block grants to give states the option to help low-income Medicare 
beneficiaries. The article concluded, however, that neither plan would be a "miracle 
cure." It pointed out that seniors with an annual income between $11,000 and $16,000 a 
year, spend more on prescription drugs than any other group. Nonetheless, individuals in 
this income bracket are not poor enough to qualify for maximum assistance under either 
plan.33 
While the article pointed out that the combination of initiatives offered under 
either plan would make prescription drugs more affordable to lower income senior 
citizens, it also concluded that neither plan would be a comprehensive solution to the 
problems caused by high prescription drug prices. Seniors cannot rely solely on the 
federal govemment to assist them in affording prescription drugs. In order to make 
prescription drugs affordable to seniors, a combination of cost cutting initiatives must be 
utilized. This section examines both the benefits and liabilities of some of these 
initiatives. 
Pharmaceutical Companies Lower Their Prices 
The most obvious way to lower the price of prescription drugs is for 
pharmaceutical companies to simply lower their prices. However, this scenario is very 
17 
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unlikely. A company would simply refuse to lower prices unless the discount was 
profitable to the company. For example, if a company reduced the cost of a certain drug 
by 15%, the move would only be profitable if the company's sales of that drug increased 
by more than 15% to cover the money lost through the discount as well as the increase in 
production costs for producing more drugs. A large increase in sales triggered by a 
discount in price is unlikely for two reasons. The first is that there is a limited customer 
base. There are only so many people that need the drug. A decrease in price would raise 
a company's market share, but would not have a dramatic increase in the sale of all of the 
drugs in the field. The end result would be that the company that discounted the drug 
would take business from other companies who would discount their prices to regain 
their respective market shares therefore rendering the discount unprofitable for the 
original company. 
Pharmaceutical companies are not pressured to lower the costs of their drugs 
while they are: under patent. Generally, any discounting that does take place occurs after 
a patent has expired unless a drug receives competition by a chemically different drug 
that treats the same disease. Once a patent does expire, competing pharmaceutical 
companies are free to enter generic drugs into the market. Generally, the emergence of 
small generic producers does not effect the price of the original drug because they make 
up a very small percentage of the market. When this occurs, it is unlikely that a company 
will cut prices because it is unlikely to recoup the revenue lost as a result of the price cut. 
Once major generic pharmaceutical firms enter the market, the price of the original drug 
is forced down. The larger firms have more money to market their drugs and promote 
18 
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them in medical journals and through direct salesmen who persuade doctors to prescribe 
the generic substitutes to the drug in order to save their patient money. 
For these reasons, a dramatic discount in the price of prescription drugs sold by 
pharmaceutical manufacturers is very unlikely. A company must be concerned with the 
profitability of its drugs. The loss of income incurred from a price cut is immediate, 
while the reduction in the quantity sold due to the entry of new products is gradua1.34 
Profits that may be attained in the future often take a backseat to an immediate decrease 
in profits. A pharmaceutical firm is reluctant to cut prices because the loss is immediate 
and the gain is merely speculative. The future is always less certain than the present, and 
an immediate cut in price is certain to reduce revenues. 34 
Formularies and Bulk Purchases 
Formularies are catalogues of pharmaceutical products and their prices. The 
function of these catalogues is to list the names of drugs, their generic equivalents, and 
the prices of each. They are intended to influence doctors and pharmacists to favor 
generic drugs. Some countries, such as Canada, have adopted the use of such formularies 
to determine the reimbursement of healthcare costs. When formularies are used 
exclusively to determine costs, the process is called mandatory price selection. When 
governments or insurance companies use mandatory price selection, it would seem that 
the winning bidder could potentially capture the entire reimbursement market. 3S 
There are some flaws to this system, however. The prices published in the 
formulary are not static, but the prices reported in the formulary are. Every six months, a 
new price for each drug is published in the formulary. The lowest submitted price is then 
designated as the reimbursement price for the drug. Once the formulary is published, a 
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pharmacist can expect to be reimbursed for the cost of the lowest available price in the 
formulary, but he is not bound to buy from that company. The pharmacist then buys the 
lowest priced drug he can. Thus, the companies enter into a second round of bidding for 
market shares. The result is that companies report a list price to the formulary of what 
they would charge if they held a monopoly on the product. If they are the only company 
listed in the formulary, then they can command that price. If other companies are 
reported in the formulary, the price is driven down, but only in the second round of 
bidding. The result of a formulary is that it truly does not drive prices down. Since drug 
companies cannot be bound to the published prices of the formulary, it is a mere 
formality. The true price pressures of the formulary rely on the market pressures in 
competing for the pharmacists' prescription, which is dependent solely on the kickback 
that the phamlacist can receive from the difference in the reimbursement costs and the 
price he or she pays for the drug. 
Another way that governments and large healthcare providers attempt to control 
the price of drugs is through buying drugs in bulk and engaging in aggressive price 
negotiations. In these negotiations, they use their large volume and cost-containment 
techniques to back up their negotiating stance.36 The largest purchasers in the United 
States are the federal and state governments through the prescription drug coverage 
extended to ŮĜŸŬŮŨŤĚon Medicaid. It is estimated that government purchases represent ten 
to fifteen percent of total sales. 37 In 1990, the government not only mandated states to set 
up drug utilization review boards to monitor which pharmaceuticals are prescribed by 
physicians, but also set up mandatory rebate levels for Medicaid purchases. The rebate 
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formula, requires drug companies to reimburse the larger of 15.7 percent of the average 
manufacturer price (AMP) or the AMP minus the best price given on the market. 36 
Through the use of formularies and bulk buying, healthcare providers, insurance 
companies, and governments have "reduced industry revenues substantially."36 
Subsequently, the costs of these drugs have gone down, but there are some inherent flaws 
in these types of price controls. The first is that by decreasing the profits of major 
pharmaceutical companies, the money available for research of new drugs is diminished. 
The second flaw is that by limiting the profits that companies are able to make off of their 
drugs, the opportunities to recoup the money invested in the research and development of 
the drugs are decreased. There are only two ways that pharmaceutical companies can 
respond. They can refuse to develop certain drugs if they see the risk associated with 
recovering the money invested outweighs the potential economic benefits of the drug for 
the pharmaceutical company, or they can increase prices on those people who do not 
benefit from the formularies, rebates, and discounts offered to bulk buyers. An article in 
Newsweek pO:lnts out that "just 26 percent of drugs in the United States will be sold at full 
price this year." 38 The article also states that the government, through negotiations and 
rebates can obtain prices of up to fifty percent off of the market price. Through 
aggressive price negotiations, HMO's and insurers can obtain prices up to forty percent 
off. This undoubtedly leads to a price increase in the costs of drugs to the uninsured, who 
do not qualify for government programs and cannot afford insurance. 
Governmental Regulation 
The rising costs of prescription drugs have led many states to look for ways to 
contain Medicaid costs. In Indiana, where the Medicaid pharmacy costs have risen 
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steadily, lawmakers are looking into ways to impose managed-care techniques, higher co-
payments, and. approved lists of drugs to control the $3.5 billion Medicaid program's 
fastest-growing expenditures.39 A graph of reported and projected spending on 
pharmaceuticals for Medicaid in Indiana is listed below. 
Indiana Me die aid D ru 9 E x pen tid u re s 
(I) 1000 "'1' , 
C 800 .. :'; ":. .;.6 
.2 (I) ŸĚ... 
.- ..! 600 :iE '[ 
---
0 <.-C C 400 
-
.... 
(I) 0 200 0 
(.) 0 
, 
1999 2000 2001 2002 2003 2004 
Yea r 
- Two ways in which lawmakers can lower the costs of statewide Medicaid is to 
eliminate services provided by Medicaid that are not required by the federal government 
and to impose: a procedure of prior authorization for certain drugs. The first scenario is 
unlikely because there is virtually no chance that elected officials would vote to end drug 
benefits, toss people out of nursing homes or stop caring for the mentally disabled, which 
are the most costly optional services.39 The second scenario is strongly opposed by 
pharmaceutical companies that argue the latest drugs are safer and more effective than 
less-expensive ones. For example, Eli Lilly and Company "strongly opposes prior 
authorization because it could deny Medicaid patients effective drug therapies they could 
not afford on their own." 39 
One example ofa way that a state can hold down the costs of prescription drugs is 
to simply cap them. In an attempt to control the costs of prescription drug benefits 
22 
--, 
.-
afforded by state Medicaid programs, the state of New Hampshire set a cap of three 
prescriptions per month on each of the Medicaid recipients. This cap was initiated in 
1981 and was projected to save the state $300,000 to $400,000 in annual drug costs. It 
was dropped after less than a year.40 During the time that the cap was in place, the 
utilization of prescription drugs by Medicaid patients fell by 35 percent. However, it was 
discovered that limiting the number of drug prescriptions placed frail, low-income, 
elderly patients at increased risk of institutionalization in nursing homes. 40 Studies of the 
program repOlted that under the cap, the elderly population had more than a 50 percent 
greater chance of being admitted to nursing homes. It was found that the state incurred 
additional costs of increased hospital, physician, and nursing home use that far 
outweighed any projected savings of the program. 
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Solutions to the Problem 
There are no quick, one step cures to the inflated costs of prescription drug prices. 
The previous section examined some methods used by governments and by large 
healthcare services to control the price of prescription drugs. While these methods are, in 
many cases, successful in holding down the cost of pharmaceuticals, they also contain 
unintended, sometimes hidden costs. The negative attributes of these programs include 
inferior treatment of patients, a decrease in pharmaceutical companies' profits which 
could lead to a decrease in the rate of discovery and development of new drugs, and the 
costs of the research and development being shifted to other customers. While many 
efforts have been made to correct the problem of rising costs, all have failed in one way 
or another. 
In order to find a solution, one must first identify the problem and set goals to 
correct it. When dealing with the rising costs of pharmaceuticals, there are no miracle 
cures. A solution must be long term and comprehensive. It must set broad, decisive 
goals that can be achieved through cooperation between the government, large healthcare 
providers, and the pharmaceutical companies to ultimately benefit the patients. There are 
two goals that must be set. The first is to lower the cost of prescription drugs to make 
them more affordable and therefore more available to patients. The second is to increase 
the quality of care given to them. 
Lowering Costs 
It is true that there has been a dramatic rise in pharmaceutical expenditures in 
recent years. According to an article in Consumer Research Magazine, "Outpatient 
expenditures on prescription drugs (with inflation taken into account) almost doubled 
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between 1990 and 1998." The share of spending on pharmaceuticals has climbed from 
4.9% of health care costs in 1985 to 7.2% in 1997.41 Despite these facts, price increases 
of pharmaceuticals cannot be blamed for this problem. The prices of pharmaceutical 
drugs have risen less than 4% annually, which is only slightly above the rate of inflation 
and far below the rate of increase in expenditures for prescription drugs since 1993. 41 
The article estimates that increases in the price of drugs can only account for up to one 
quarter of the increase in pharmaceutical expenditures. The other 75% is attributed to 
several other factors. 
The first such factor is the aging baby boom generation. Individuals in this 
generation are approaching the age of fifty. Their increasing age is a major contributor to 
the increase in the volume of drugs prescribed because older patients tend to have more 
chronic and severe cases of disease or mUltiple conditions, each of which may require 
more treatment. 42 The baby boom generation encompasses approximately 77 million 
United States citizens or roughly 30% of the U.S. population. As their generation 
continues to age, an increase in the volume of drugs prescribed will continue to rise. The 
demographic shift toward an older population in the United States provides evidence that 
the problem of rising healthcare costs will continue to get worse, unless something is 
done to correct it. 
Nothing can be done to counteract the effects of an aging population except to cut 
costs in other ways. There are several other variables that account for the increase in 
costs of healthcare. Among others, they include the increase in diagnosis of diseases 
across the board, the high costs of advertising promotions, the need for pharmaceutical 
companies to make profits in order to fund additional research, and the piracy of patented 
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products. The increase in diagnosis stems both from an increase in ailments of an aging 
population as well as the use of better techniques to detect diseases. Once again, the 
increase in diagnosis is a contributing factor in the rising costs of health care, but there is 
nothing we can do to control it. 
As discussed in the first section, the rising costs of the promotion of 
pharmaceuticals, about $6 billion in 1998, are a contributing factor in the price of the 
drugs. 43 Pharmaceutical companies justify these costs by pointing to the need to educate 
doctors about new drugs and their uses. In order to help curb these costs, the federal 
government should institute an independent, nonpartisan review board to examine the 
performance of drugs during clinical testing. The board could then summarize the results 
of its research and report the uses, benefits, and side effects of drugs to doctors. In this 
way, the money that is currently being spent toward the promotion of drugs could be 
greatly reduced, and therefore lead to an across the board decrease in the price of 
pharmaceuticals. 
The need for pharmaceutical companies to make a profit in order to recoup the 
large amounts of money spent on research and development, as outlined in the beginning 
of the second section, is an important consideration to take into account when looking for 
a way to cut pharmaceutical costs. Newsweek reports that in 1999, the pharmaceutical 
industry was the highest rated industry with respect to return on revenues, return on 
assets, and return on shareholders' equity.44 During his bid for presidential office in 
2000, Al Gore blasted drug companies for "gouging the consumer unfairly." 44 Merck 
public-policy executive Ian Spatz best echoes the industry's response. In refuting the 
claim that drug company profits are excessive, he argued that Gore was not taking the 
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high risks associated with drug discovery into account. He argued, "If we are successful, 
if we develop great new medicines that have value, we should be profitable." 44 Without 
setting price controls and regulating the industry's profit margins, there is little that the 
government can do with respect to the financial success of pharmaceutical companies. 
The fact that pharmaceutical companies currently return better than average profits is not 
necessarily a bad thing. In fact, it benefits consumers of pharmaceuticals in several ways 
such as encouraging new companies to enter the market and providing money for 
research of other new drugs. 
The piracy of patented products has to do with the lack of enforcement of patents 
in other countries. The Congressional Research Service estimates that U.S. companies 
lose approximately "one dollar to inadequate protection of intellectual property rights for 
every three dollars of revenue gained from exported products." 45 In other words, U.S. 
companies lose up to $80 billion dollars a year because of inadequately enforced 
intellectual property rights. 46 These losses effect all companies that export goods and 
cause the companies to raise prices for other consumers to cover these losses. These 
losses are particularly prominent in the pharmaceutical industry due to the ease of 
duplication of the products. 
In order to minimize the effects of weak intellectual property law enforcement in 
other countries, the United States government must actively lobby the governments of 
other countries to strengthen the framework of their intellectual property laws. The 
problems of patent piracy stem not just from the nonexistence of intellectual property 
laws but also from the lack of enforcement of existing laws. The United States 
government must lobby these governments through the use of treaties, trade agreements, 
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and diplomatic negotiations. Through working to limit the money lost overseas to the 
piracy of inteLlectual property rights, the government can play an active role in decreasing 
the price of pr'escription drugs in the United States across the board. 
Increasing the Quality of Care 
While the issue of the costs of prescription drugs is important in the respect that it 
affects the availability of the drugs to the public, the benefits of new drugs and 
pharmaceutical research far outweigh the costs. Prescription drugs are estimated to only 
represent seven percent of total health care expenditures, 47 yet they have reduced 
mortality and morbidity rates more than any other scientific advances. 48 The costs of 
prescription drugs can be quantitized, however the benefits cannot. The book, Changing 
Environment for u.s. Pharmaceuticals points out that "for many diseases, drug therapy 
obviates the need for mare drastic and expensive forms oftreatment such as 
hospitalization and surgery." 49 
In tallying the true benefits of drugs, one must tally up the costs of disease. 
Public opinion often focus on the monetary costs of prescription drugs, but no one ever 
gives the pharmaceutical companies credit for saving the consumers the monetary, 
physical, and emotional stresses of having a disease. Prescription drugs benefit society by 
shortening or eliminating the need for long hospital stays, saving people from potentially 
fatal diseases, enabling people to return to work sooner, and allowing people to live 
longer and healthier lives. For these reasons, it is important to allow pharmaceutical 
companies to continue to make large returns on their investments. This encourages new 
investments by the industry and by new companies entering the market. This leads to 
additional research to find new cures that will benefit society. 
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A simple example of how the discovery of a drug can benefit society is the 
introduction of H2 antagonists in 1977. These drugs are used to help treat ulcers, and the 
result is the rate of surgical operations for ulcers has dropped from 155,000 to around 
16,000 per year. 50 Considering that an ulcer surgery costs approximately $25,000 and 
the drugs costs approximately $1,000, this implies a net cost savings of over $3 billion 
per year.51 However, this estimate only takes the costs ofthe surgery and the drugs into 
account. It ignores any savings resulting in shorter hospital stays, an earlier return to 
work for the patient, and less suffering for the patient. 
The previous case points out how prescription drugs truly benefit society and why 
additional ŲŤVĜŸŠŲȘUĚshould be done to discover new drugs. Research should not only be 
done to find cures for currently incurable diseases, but also to research current drugs to 
identify any additional uses they may have. An example of this is the current research of 
aspirin. Through this research, it has been discovered that an aspirin regiment reduces 
heart attacks, strokes, and angina through improving blood flow through the arteries by 
making it less sticky and less likely to clot.52 Other research should be done on other 
drugs to discover any other possible health benefits that they may have. 
Additional research can be considered both a way to cut costs and a way to 
improve care. However, all of the research does not have to be done by the 
pharmaceutical company itself. For example, the government could research the FDA 
approval process in order to find ways to make it quicker, safer, and more efficient to 
approve drugs. Also, the government could take advantage of collegiate researchers to 
aid in the discovery of new drugs. Through offering more grants and possibly even tax 
breaks to companies who involve undergraduate and graduate researchers, the process of 
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discovery can be accelerated, and universities would be furnished with new sources of 
income to update equipment and to better educate their students through practical 
experiences. 
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